Netupitant/palonosetron - Helsinn

Drug Profile

Netupitant/palonosetron - Helsinn

Alternative Names: Akynzeo; Fosnetupitant/palonosetron; IV Fosnetupitant/Palonosetron; IV NEPA FDC; NEPA - Helsinn; NEPA IV; Netupitant-palonosetron fixed dose combination (NEPA); Palonosetron/netupitant

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helsinn
  • Developer Glenmark Pharmaceuticals Ltd; Helsinn; Purdue Pharma; Taiho Pharmaceutical; Vifor Pharma
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 04 Apr 2018 Netupitant/palonosetron licensed to Glenmark Pharmaceuticals in India and Nepal
  • 20 Mar 2018 The US FDA assigns PDUFA action date of 20/04/2018 for netupitant/palonosetron for Chemotherapy induced nausea and vomiting (IV)
  • 20 Mar 2018 Preregistration for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV) prior to March 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top